DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION EFFICACY TRIALS
VIRTUAL WORKSHOP SERIES
OCTOBER 2020 to MAY 2021
HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic.
As a result, the design and conduct of the next generation of prevention trials is impacted and is further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.
The second session of the virtual workshop aims to reflect on future trial designs for ARV-based prevention strategies, HIV vaccines and monoclonal antibodies. This session is supported by a further six bite-size presentations and three panel discussions of the current scientific approaches for establishing efficacy of vaccines in the broader context or Pre-Exposure Prophylaxis (PrEP).
PANEL DISCUSSION 2A – Friday 06 November 2020.
Future Design Approaches For Trials Of Antiretroviral-Based Prevention Strategies
PANEL DISCUSSION 2B – Wednesday 18 November 2020.
Future Design Approaches for HIV Vaccine Efficacy Trials
PANEL DISCUSSION 2C – Thursday 8 April 2021.
Research pathway for the use of monoclonal antibodies in HIV prevention.
Lawrence Corey, M.D.
Fred Hutchinson Cancer Research Center, USA.
A Research for Prevention // Virtual event.
|Inferring HIV incidence using incidence of other STIs||Jared Baeten, M.D., Ph.D. – University of Washington, Seattle, USA.|
|Cross-sectional HIV incidence estimation using recent infection assays and algorithms – A statistical perspective||Eduard Grebe, Ph.D – Vitalant Research Institute, San Francisco, USA.|
|Cross-sectional incidence assays to infer population incidence – Clinical trial perspective||Sinéad Delany-Moretlwe, MBBCh Ph.D. DTM&H – Wits RHI, South Africa.|
|Using of a surrogate endpoint in licensure of pneumococcal vaccines||David Radley, M.Sc. – Pfizer Inc. – New York, USA.|
|A case study in using extra-trial data to infer placebo incidence||Mia Moore, Ph.D. – Fred Hutchinson Cancer Research Center, Seattle, USA.|
|Future directions for more granular estimation of HIV incidence||Jeffrey W. Eaton, Ph.D. – Imperial College London, UK.|
Jared Baeten, M.D., Ph.D.
University of Washington, Seattle, USA.
Eduard Grebe, Ph.D.
Vitalant Research Institute, San Francisco, USA.
Sinéad Delany –Moretwe, MBBCh, Ph.D., DTM&H
Wits RHI, South Africa.
David Radley, M.Sc.
Pfizer Inc., USA.
Mia Moore, Ph.D.
Fred Hutchinson Cancer Research Center, Seattle, USA.
Jeffrey W. Eaton, Ph.D.
Imperial College London, London, UK.
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
IAS – the International AIDS Society
Avenue de France 23
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: